Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

• Market Cap: ₹11.30B
• Dividend Yield: 1.24%
• Average Volume (3M): 3.85K
• Price to Earnings (P/E): 27.5
• Beta (1Y): 1.33
• Revenue Growth: 24.60%
• EPS Growth: 153.56%
• Country: IN
• Employees: 1,025
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.64
• Shares Outstanding: 66,781,270
• 10 Day Avg. Volume: 3,534
• 30 Day Avg. Volume: 3,854
• PEG Ratio: 0.18
• Price to Book (P/B): 6.09
• Price to Sales (P/S): 5.44
• P/FCF Ratio: 26.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ₹184.00 ▼(-4.91% Downside)

Jagsonpal Pharmaceuticals Ltd. shows strong financial health with consistent growth and profitability, which is the most significant factor in its stock score. However, technical indicators reflect a bearish trend, and the valuation is moderate with limited dividend appeal. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue growth trend

Sustained ~11% revenue growth signals expanding product adoption and market penetration across therapeutic areas. Over a 2-6 month horizon this underpins recurring sales, provides room to scale SG&A efficiently, and supports reinvestment in R&D and distribution.

Healthy margins and operational efficiency

Robust gross and net margins plus rising EBIT/EBITDA margins indicate durable cost control and pricing power. This structural profitability makes earnings less sensitive to cyclical revenue dips, enabling steady cash generation and funding for strategic initiatives over the medium term.

Low leverage and strong equity base

A high equity ratio and low debt levels reduce financial risk and interest burden, granting flexibility for acquisitions, capex or downturns without heavy refinancing. This balance sheet strength supports sustainable growth and resilience across multi-quarter cycles.

Negative Factors

Declining cash and short-term investments

A falling cash balance erodes the company’s liquidity buffer and increases reliance on working capital efficiency or external financing. Over several months this can constrain timely capex, product launches, or buffer against supply disruptions, raising execution risk.

Negative EPS growth

A material decline in EPS suggests earnings contraction or one-off impacts that reduce shareholder returns capacity. If EPS trends remain negative over multiple quarters it limits retained earnings for R&D, weakens dividend sustainability and can pressure long-term investor confidence.

Variable free cash flow growth

Fluctuating free cash flow growth points to inconsistent conversion of profit into usable cash, perhaps from capex swings or working capital variability. This makes long-range planning for dividends, debt repayment, and strategic investments less predictable and raises execution risk.

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.

How the Company Makes Money

Jagsonpal Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products in domestic and international markets. The company produces a variety of formulations and markets them to hospitals, pharmacies, and healthcare providers. Key revenue streams include the sales of prescription drugs, over-the-counter medications, and specialty healthcare products. Additionally, Jagsonpal Pharmaceuticals may engage in partnerships with other pharmaceutical companies for co-marketing agreements, distribution deals, and licensing of products, which can enhance its earnings. The company's focus on research and development also allows it to innovate new products, potentially leading to new revenue opportunities.

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Jagsonpal Pharmaceuticals Ltd. exhibits strong financial performance with robust revenue growth, healthy profit margins, and a solid balance sheet. The company demonstrates efficient cost management and operational efficiency, although there is some concern regarding liquidity due to declining cash reserves.

Income Statement

Jagsonpal Pharmaceuticals Ltd. has demonstrated strong revenue growth over the years, with a notable increase in net income as well. Gross profit margin and net profit margin are healthy, indicating efficient cost management and profitability. The increase in EBIT and EBITDA margins further underscores the company's operational efficiency. Overall, the income statement reflects a robust and growing financial performance.

Balance Sheet

The company's balance sheet is solid, characterized by a strong equity base and a low debt-to-equity ratio, indicating low leverage and financial stability. The equity ratio is high, showcasing a strong asset base funded by equity rather than debt. This structure mitigates financial risk and provides a foundation for sustainable growth. However, the decline in cash and short-term investments over time could be a point of concern for liquidity management.

Cash Flow

Cash flow analysis shows a positive trajectory in operating cash flow and free cash flow, which supports the company's capacity to reinvest and pay dividends. The operating cash flow to net income ratio is strong, highlighting effective conversion of earnings into cash. However, the free cash flow growth rate has shown some variability, which could indicate fluctuations in capital expenditures or cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.83B	2.69B	2.09B	2.37B	2.18B	1.88B
Gross Profit	1.60B	1.72B	652.59M	1.44B	1.28B	1.07B
EBITDA	847.59M	510.71M	323.46M	363.96M	284.53M	234.72M
Net Income	608.27M	553.61M	224.63M	267.21M	188.55M	170.58M
Balance Sheet
Total Assets	0.00	2.78B	2.17B	1.95B	1.68B	1.64B
Cash, Cash Equivalents and Short-Term Investments	1.29B	1.29B	1.48B	1.15B	472.77M	618.82M
Total Debt	0.00	92.39M	89.41M	60.01M	52.47M	67.88M
Total Liabilities	-2.40B	383.10M	296.76M	360.56M	375.99M	422.73M
Stockholders Equity	2.40B	2.40B	1.87B	1.59B	1.31B	1.22B
Cash Flow
Free Cash Flow	0.00	549.52M	349.18M	463.37M	51.31M	277.53M
Operating Cash Flow	0.00	553.00M	351.66M	466.54M	55.98M	282.22M
Investing Cash Flow	0.00	-451.47M	-245.48M	-576.71M	-257.79M	-22.64M
Financing Cash Flow	0.00	-116.98M	-89.11M	-4.57M	-175.52M	-68.28M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 193.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 193.5 is above the 20-day moving average (MA) of 174.86, above the 50-day MA of 191.45, and below the 200-day MA of 221.06, indicating a bearish trend. The MACD of -8.58 indicates Positive momentum. The RSI at 37.19 is Neutral, neither overbought nor oversold. The STOCH value of 44.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	74 Outperform	₹18.71B	17.02	―	0.28%	7.51%	71.81%
LINCOLN	74 Outperform	₹9.16B	11.46	―	0.37%	―	―
JAGSNPHARM	67 Neutral	₹11.30B	27.54	―	1.24%	24.60%	153.56%
HESTERBIO	61 Neutral	₹12.61B	30.81	―	0.44%	-3.84%	86.82%
THEMISMED	54 Neutral	₹7.41B	-27.46	―	0.48%	-18.86%	-150.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAJAJHCARE	51 Neutral	₹10.96B	22.01	―	0.24%	13.04%	―

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts

Jagsonpal Pharmaceuticals Ltd. has published newspaper advertisements in the English and Hindi editions of Business Standard containing extracts of its unaudited financial results for the quarter and nine-month period ended 31 December 2025, in compliance with Regulation 47 of SEBI’s Listing Obligations and Disclosure Requirements. By formally notifying the stock exchanges of this disclosure, the company is reinforcing its regulatory compliance and transparency obligations to investors and other stakeholders regarding its interim financial performance.

Jagsonpal Pharma Board Approves Unaudited Q3 and Nine-Month FY25 Results

Jagsonpal Pharmaceuticals Ltd. announced that its Board of Directors has approved the unaudited financial results for the quarter and nine-month period ended December 31, 2025. The results, which have undergone a limited review by the company’s statutory auditors in line with Indian Accounting Standards and SEBI’s listing regulations, mark a key disclosure for investors and regulators, reinforcing ongoing compliance with financial reporting norms and providing stakeholders with updated visibility on the company’s financial performance for the current fiscal year to date.

Jagsonpal Pharmaceuticals Schedules Analyst and Investor Meeting

Jagsonpal Pharmaceuticals Ltd. has announced a scheduled meeting with analysts and institutional investors on November 25, 2025, in Mumbai. This meeting, part of the company’s ongoing investor relations efforts, aims to discuss publicly available information, ensuring transparency and engagement with stakeholders without disclosing any unpublished price-sensitive information.